Cargando…

Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis

PURPOSE: The prognosis of patients with advanced and recurrent urothelial cancer (UC) is poor. Although cisplatin (CDDP)-containing chemotherapy is the most effective regimen in these patients, there is no other established chemotherapeutic regimen. We administered combination therapy with low-dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyata, Yasuyoshi, Nomata, Koichiro, Ohba, Kojiro, Matsuo, Tomohiro, Sagara, Yuji, Kanetake, Hiroshi, Sakai, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428519/ https://www.ncbi.nlm.nih.gov/pubmed/22864875 http://dx.doi.org/10.1007/s00280-012-1938-3

Ejemplares similares

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34
por: Miyata, Yasuyoshi, et al.
Publicado: (2013)

A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis
por: Miyata, Yasuyoshi, et al.
Publicado: (2017)

Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2018)

High Expression of HuR in Cytoplasm, but Not Nuclei, Is Associated with Malignant Aggressiveness and Prognosis in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2013)

Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
por: Asai, Akihiro, et al.
Publicado: (2016)

Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder
por: Matsuo, Tomohiro, et al.
Publicado: (2019)

Recovery from life-threatening pelvic organ prolapse in an 80-year-old Japanese woman: a case report
por: Matsuo, Tomohiro, et al.
Publicado: (2014)

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men
por: Matsuo, Tomohiro, et al.
Publicado: (2016)

Renoprotective effects of telmisartan after unilateral renal ablation in rats
por: Matsuo, Tomohiro, et al.
Publicado: (2013)

Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers
por: Miyata, Yasuyoshi, et al.
Publicado: (2020)

Neoadjuvant hormonal therapy for low‐risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis‐related parameters
por: Miyata, Yasuyoshi, et al.
Publicado: (2017)

Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract
por: Miyata, Yasuyoshi, et al.
Publicado: (2012)

Left atrial metastasis of renal cell carcinoma: a case report and review of the literature
por: Ohba, Kojiro, et al.
Publicado: (2014)

A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants
por: Miyata, Yasuyoshi, et al.
Publicado: (2019)

Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie’s Disease
por: Miyata, Yasuyoshi, et al.
Publicado: (2021)

Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2020)

Met in Urological Cancers
por: Miyata, Yasuyoshi, et al.
Publicado: (2014)

Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial
por: Araki, Kyohei, et al.
Publicado: (2018)

Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2
por: Araki, Kyohei, et al.
Publicado: (2020)

Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake
por: Matsuo, Tomohiro, et al.
Publicado: (2021)

Excessive accumulation of visceral fat is associated with lower urinary symptoms including overactive bladder in female patients
por: Otsubo, Asato, et al.
Publicado: (2020)

Presurgical bladder wall thickness is a useful marker to predict the postsurgical improvement of symptoms in patients with pelvic organ prolapse‐related overactive bladder
por: Otsubo, Asato, et al.
Publicado: (2021)

A pilot study to assess the safety and usefulness of combined transurethral endoscopic mucosal resection and en-bloc resection for non-muscle invasive bladder cancer
por: Hayashida, Yasushi, et al.
Publicado: (2019)

Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
por: Yuno, Tsutomu, et al.
Publicado: (2020)

Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer
por: Matsuo, Tomohiro, et al.
Publicado: (2017)

Relationship between Urinary Calcium Excretion and Lower Urinary Tract Symptoms
por: Matsuo, Tomohiro, et al.
Publicado: (2022)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
por: Ito, Hidenori, et al.
Publicado: (2022)

Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report
por: Kojima, Yasuyuki, et al.
Publicado: (2015)

Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
por: Kattan, Joseph G, et al.
Publicado: (2012)

Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1
por: Mukae, Yuta, et al.
Publicado: (2020)

Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia
por: Mitsunari, Kensuke, et al.
Publicado: (2021)

Effect of oral intake of royal jelly on endothelium function in hemodialysis patients: study protocol for multicenter, double-blind, randomized control trial
por: Ohba, Kojiro, et al.
Publicado: (2021)

Periodontal Disease in Patients Receiving Dialysis
por: Miyata, Yasuyoshi, et al.
Publicado: (2019)

Pathological Characteristics of Periodontal Disease in Patients with Chronic Kidney Disease and Kidney Transplantation
por: Kitamura, Mineaki, et al.
Publicado: (2019)

Pathological significance and prognostic role of LATS2 in prostate cancer
por: Matsuda, Tsuyoshi, et al.
Publicado: (2021)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies
por: Miyata, Yasuyoshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i0f8kbmi1keiie963hr2066qmp